CoChat

A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease

Tse, Chung Sang, Singh, Siddharth, Sandborn, William J · 2022 · Inflammatory Bowel Diseases

The DOI matches its Crossref record; 78 of the 87 references it cites were found in a registry or an index.

Abstract

A growing body of evidence from preclinical, translational, and clinical studies supports a bidirectional relationship within the gut-brain axis that contributes to neurobiological symptoms including anxiety, depression, fatigue, stress, and sleep disturbance. These symptoms have a significant impact on health-related quality of life and functional ability in individuals with inflammatory bowel disease. Clinical studies that generate high-quality evidence on pharmacological and nonpharmacological (eg, psychosocial, behavioral) interventions are needed to ultimately improve access to safe and effective therapies that have a meaningful impact on patients and to guide medical and regulatory decisions. This review outlines a framework for designing and conducting randomized controlled trials for interventions that target neurobiological symptoms in patients with inflammatory bowel disease based on the most recent guidance published within the past 5 years from policy makers, clinicians specialized in inflammatory bowel disease, patient-reported outcomes methodologists, health economists, patient advocates, industry representatives, ethicists, and clinical trial experts. © 2021 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved.

Overview

Integrity signals

Registry

Crossref · 10.1093/ibd/izab153

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 78 references

Research works printed but not linked: 17

  1. U.S. Food & Drug Administration., 2021, Code of Federal Regulations Title 21
  2. U.S. Food & Drug Administration., 2019, E8(R1) General considerations for clinical studies
  3. U.S. Food & Drug Administration., 2016, BEST (Biomarkers, EndpointS, and other Tools) Resource.
  4. European, 1998, ICH E8 General considerations for clinical trials
  5. U.S. Food & Drug Administration., DDT COA #000015: PROMIS® Short Form Fatigue 10a in Rheumatoid Arthritis
  6. U.S. Food & Drug Administration., 2017, Multiple endpoints in clinical trials guidance for industry.
  7. U.S. Food & Drug Administration., 2018, methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments
  8. U.S. Food & Drug Administration., 2019, incorporating clinical outcome assessments into endpoints for regulatory decision making
  9. U.S., 2020, Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation
  10. U.S. Food & Drug Administration., 2018, Patient-focused drug development: collecting comprehensive and representative input
  11. Campbell, 2013, FDA guidance: design considerations for pivotal clinical investigations for medical devices
  12. Canadian Agency for Drugs and Technologies in Health., 2016, Entyvio (vedolizumab). Appendix 5: validity of outcome measures
  13. HealthMeasures., 2021, PROMIS® Score Cut Points
  14. Slagle, 2015, A Regulatory Perspective on Disease-Specific Outcome Measures: How does PROMIS Fit?
  15. Cohen, 1988, Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds, The social psychology of health. Sage Publications, Inc.;, 31
  16. Spielberger, 1989, State-Trait Anxiety Inventory: A Comprehensive Bibliography.
  17. Beck, 1996, Manual for the Beck Depression Inventory–II., San Antonio, TX: Psychological Corporation

Cited by

See all 3

Metadata

Authors
Tse, C. S., Singh, S., & Sandborn, W. J.
Affiliations
University of California San Diego (US)
Corresponding author
Sandborn, William J
Venue
Inflammatory Bowel Diseases
Published
2021-07-09
Volume
28
Issue
5
Pages
788-800
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
OpenAlex
W3181381795
Cited by
3
References
87
Citations by year
2026: 1 · 2025: 2
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Locations
  • Inflammatory Bowel Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords
gut-brain axis, inflammatory bowel disease
MeSH terms
Brain-Gut Axis, Anxiety, Chronic Disease, Depression, Humans, Quality of Life, Sleep Wake Disorders, Inflammatory Bowel Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1093/ibd/izab153
The paper
Tse, C. S., Singh, S., & Sandborn, W. J. (2022). A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izab153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.